DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
datopotamab - 1 AstraZeneca - 1 British drugmaker - 1 Kelun - 1 Maggie Fick - 1 Ludwig Burger - 1 Sinchita Mitra - 1 Lucy Raitano - 1
Top related locs:
British Biotech of China London Frankfurt Bengaluru
Top related orgs:
AstraZeneca - 1 Japan's - 1 Merck & Co - 1 Biotech of - 1 Barclays - 1 Thomson - 1

Search resuls for: "Biotech of"


2 mentions found


☆ AstraZeneca shares drop as lung cancer trial update lags expectations
  + stars: | 2023-07-03 | by ( Maggie Fick Ludwig Burger | Maggie Fick | Ludwig Burger | ) www.reuters.com   time to read: +3 min
July 3 (Reuters) - AstraZeneca (AZN.L) said on Monday an experimental precision drug slowed progression of lung cancer in a late-stage trial, but the company's shares fell as much as 6% as analysts said the benefits may not be as pronounced as hoped. It declined to provide more trial details, saying they would be presented at an as yet undisclosed medical conference. At 0855 GMT, shares in AstraZeneca were down 5.8% at their lowest level in more than three months. Gilead (GILD.O) has pioneered the targeting of TROP2 with an ADC named Trodelvy, approved to treat certain types of breast and bladder cancer. AstraZeneca said that the datopotamab deruxtecan trial would continue as planned to assess the effect of the drug on overall survival of patients, another important efficacy criterion.
Persons: datopotamab, AstraZeneca, British drugmaker, Kelun, Maggie Fick, Ludwig Burger, Sinchita Mitra, Lucy Raitano, Krishna Chandra Eluri, Susan Fenton Organizations: AstraZeneca, Japan's, Merck & Co, Biotech of, Barclays, Thomson Locations: British, Biotech of China, London, Frankfurt, Bengaluru
☆ Health-care stocks are looking good for 2023 and not just because the sector is a 'safe haven'
  + stars: | 2022-12-21 | by ( Christina Cheddar Berk | ) www.cnbc.com   time to read: +9 min
Investors looking for cover this year would have done well if they sought a safe haven in large-cap pharmaceutical stocks, a trend that is likely to continue into 2023. The Inflation Reduction Act provided some clarity around drug pricing that should help health-care stocks. The average price target, according to FactSet, is $62, or nearly 40% above the stock's closing price on Tuesday. Gene therapies in focus Investors will be closely watching the progress of several gene therapies, according to Phipps. "Yes, these are expensive therapies," Phipps said.
0 next >>
Total: 2